2017_SBRT_Course Book

Overview

1. General outline 2. SBRT combined with targeted drugs 3. SBRT combined with immunotherapy 4. Safety of SBRT combined with novel drugs

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

9

/

Rational for combining targeted drugs & SRT

Nivolumab in unselected patients

Gefitinib in mutant EGFR

Crizotinib in ALK positive

Maemondo NEJM 2010

Shaw NEJM 2013

Brahmer NEJM 2015

Ø Substantial and clinically relevant improvement Ø Still: 60 – 80% develop PD after 12 months

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

10

/